“Possible with conditions” is never our opinion. Each amber compound in the provider field guide points to the FDA list, page, or meeting it rests on. The label is free; the link and quote open with the unlock.
The shared FDA framework
7 FDA sources every amber call rests on, read on 2026-10-16: the 503A category lists, the interim compounding policy, the compounding safety-risk page, and how the Pharmacy Compounding Advisory Committee works.
- 503A category list PDF 'Updated May 14, 2026': BPC-157 does not appear in Category 1, 2 or 3.
- FDA 503A bulks page (current as of 05/14/2026): Category 1 enforcement policy.
- Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A (Guidance, January 2025), p.11: Category 1 definition.
- Interim Policy guidance (January 2025), p.13: substances outside the policy.
- FDA safety-risks page (current as of 04/22/2026): heading of the table these peptides sit in.
- FDA PCAC meeting page: advisory committees are non-binding.
- FDA PCAC meeting page Event Materials (current as of 08/06/2026): no minutes, transcript or vote summary posted; latest items are FDA presentations.
- FDA: Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (current as of 10/01/2026) - when compounding may be appropriate. FDA: Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (current as of 10/01/2026) - when compounding may be appropriate
- FDA GLP-1 page: salt forms. FDA GLP-1 page: salt forms
- FDA GLP-1 page: no lawful basis for salt forms. FDA GLP-1 page: no lawful basis for salt forms
- FDA GLP-1 page: dosing errors with compounded semaglutide. FDA GLP-1 page: dosing errors with compounded semaglutide
- FDA GLP-1 page: adverse-event counts. FDA GLP-1 page: adverse-event counts
- FDA GLP-1 page: retatrutide / cagrilintide (relevant to 'compounded GLP-1' menus). FDA GLP-1 page: retatrutide / cagrilintide (relevant to 'compounded GLP-1' menus)
What is not on an FDA page: The field guide's line that shortage status changes what pharmacies will defend is not on the FDA GLP-1 page today; it rests on the FDA drug shortages database, which the guide also cites.
- FDA safety-risks page (current as of 04/22/2026): BPC-157 stated risk. FDA safety-risks page (current as of 04/22/2026): BPC-157 stated risk
- FDA safety-risks page: BPC-157 information gap. FDA safety-risks page: BPC-157 information gap
- FDA PCAC meeting page, July 23-24, 2026 (current as of 08/06/2026): agenda. FDA PCAC meeting page, July 23-24, 2026 (current as of 08/06/2026): agenda
- FDA Briefing Document Introduction, July 23-24, 2026 PCAC: nomination status. FDA Briefing Document Introduction, July 23-24, 2026 PCAC: nomination status
- FDA PCAC presentation slides, July 2026: FDA's own position on BPC-157. FDA PCAC presentation slides, July 2026: FDA's own position on BPC-157
- FDA PCAC Questions document: voting question. FDA PCAC Questions document: voting question
What is not on an FDA page: The July 2026 PCAC vote outcome for BPC-157. FDA's meeting page posts the agenda, briefing documents, voting questions and FDA's own July 23 slides proposing NOT to list it, but no minutes, transcript or vote tally. Reports of the vote come only from non-FDA sources, so PeptIQ.io does not cite or repeat them. Today BPC-157 is not in 503A Category 1, 2 or 3; it sits on the safety-risk page as nominated but withdrawn, previously Category 2, so the Category 1 interim enforcement policy does not apply to it.
- FDA safety-risks page (current as of 04/22/2026): 'Thymosin beta-4, fragment (LKKTETQ), also known as TB-500' stated risk. FDA safety-risks page (current as of 04/22/2026): 'Thymosin beta-4, fragment (LKKTETQ), also known as TB-500' stated risk
- FDA safety-risks page: TB-500 information gap. FDA safety-risks page: TB-500 information gap
- FDA PCAC meeting page: TB-500 use evaluated. FDA PCAC meeting page: TB-500 use evaluated
- FDA PCAC presentation slides, July 2026: FDA's own position on TB-500. FDA PCAC presentation slides, July 2026: FDA's own position on TB-500
What is not on an FDA page: The July 2026 PCAC vote outcome for TB-500. FDA's meeting page posts the agenda, briefing documents, voting questions and FDA's own July 23 slides proposing NOT to list it, but no minutes, transcript or vote tally. Reports of the vote come only from non-FDA sources, so PeptIQ.io does not cite or repeat them. Today TB-500 is not in 503A Category 1, 2 or 3; it sits on the safety-risk page as nominated but withdrawn, previously Category 2, so the Category 1 interim enforcement policy does not apply to it.
- FDA safety-risks page (current as of 04/22/2026): 'MOTs-C' stated risk. FDA safety-risks page (current as of 04/22/2026): 'MOTs-C' stated risk
- FDA safety-risks page: MOTS-c information gap. FDA safety-risks page: MOTS-c information gap
- FDA PCAC meeting page: MOTS-c uses evaluated. FDA PCAC meeting page: MOTS-c uses evaluated
- FDA PCAC presentation slides, July 2026: FDA's own position on MOTS-c. FDA PCAC presentation slides, July 2026: FDA's own position on MOTS-c
What is not on an FDA page: The July 2026 PCAC vote outcome for MOTS-c. FDA's meeting page posts the agenda, briefing documents, voting questions and FDA's own July 23 slides proposing NOT to list it, but no minutes, transcript or vote tally. Reports of the vote come only from non-FDA sources, so PeptIQ.io does not cite or repeat them. Today MOTS-c is not in 503A Category 1, 2 or 3; it sits on the safety-risk page as nominated but withdrawn, previously Category 2, so the Category 1 interim enforcement policy does not apply to it.
- FDA safety-risks page (current as of 04/22/2026): 'Semax (heptapeptide)' stated risk. FDA safety-risks page (current as of 04/22/2026): 'Semax (heptapeptide)' stated risk
- FDA PCAC meeting page, July 23-24, 2026 (current as of 08/06/2026): July 24 agenda. FDA PCAC meeting page, July 23-24, 2026 (current as of 08/06/2026): July 24 agenda
- FDA PCAC meeting page: Semax uses evaluated. FDA PCAC meeting page: Semax uses evaluated
- FDA PCAC presentation slides, July 2026: FDA's own position on Semax. FDA PCAC presentation slides, July 2026: FDA's own position on Semax
What is not on an FDA page: The July 2026 PCAC vote outcome for Semax. FDA's meeting page posts the agenda, briefing documents, voting questions and FDA's own July 24 slides proposing NOT to list it, but no minutes, transcript or vote tally. Reports of the vote come only from non-FDA sources, so PeptIQ.io does not cite or repeat them. Today Semax is not in 503A Category 1, 2 or 3; it sits on the safety-risk page as nominated but withdrawn, previously Category 2, so the Category 1 interim enforcement policy does not apply to it.
- FDA safety-risks page (current as of 04/22/2026): Epitalon stated risk. FDA safety-risks page (current as of 04/22/2026): Epitalon stated risk
- FDA PCAC meeting page, July 23-24, 2026 (current as of 08/06/2026): July 24 agenda. FDA PCAC meeting page, July 23-24, 2026 (current as of 08/06/2026): July 24 agenda
- FDA PCAC meeting page: Epitalon use evaluated. FDA PCAC meeting page: Epitalon use evaluated
- FDA PCAC presentation slides, July 2026: FDA's own position on Epitalon. FDA PCAC presentation slides, July 2026: FDA's own position on Epitalon
What is not on an FDA page: The July 2026 PCAC vote outcome for Epitalon. FDA's meeting page posts the agenda, briefing documents, voting questions and FDA's own July 24 slides proposing NOT to list it, but no minutes, transcript or vote tally. Reports of the vote come only from non-FDA sources, so PeptIQ.io does not cite or repeat them. Today Epitalon is not in 503A Category 1, 2 or 3; it sits on the safety-risk page as nominated but withdrawn, previously Category 2, so the Category 1 interim enforcement policy does not apply to it.
- FDA safety-risks page (current as of 04/22/2026): KPV stated risk. FDA safety-risks page (current as of 04/22/2026): KPV stated risk
- FDA PCAC meeting page: KPV uses evaluated. FDA PCAC meeting page: KPV uses evaluated
- FDA PCAC presentation slides, July 2026: FDA's own position on KPV. FDA PCAC presentation slides, July 2026: FDA's own position on KPV
What is not on an FDA page: The July 2026 PCAC vote outcome for KPV. FDA's meeting page posts the agenda, briefing documents, voting questions and FDA's own July 23 slides proposing NOT to list it, but no minutes, transcript or vote tally. Reports of the vote come only from non-FDA sources, so PeptIQ.io does not cite or repeat them. Today KPV is not in 503A Category 1, 2 or 3; it sits on the safety-risk page as nominated but withdrawn, previously Category 2, so the Category 1 interim enforcement policy does not apply to it.
- FDA safety-risks page (current as of 04/22/2026): 'GHK-Cu (for injectable routes of administration)' stated risk. FDA safety-risks page (current as of 04/22/2026): 'GHK-Cu (for injectable routes of administration)' stated risk
- 503A category list PDF 'Updated May 14, 2026': NON-injectable GHK-Cu is in Category 1; injectable is not. 503A category list PDF 'Updated May 14, 2026': NON-injectable GHK-Cu is in Category 1; injectable is not
- 503A category list PDF (May 14, 2026): why the injectable route dropped out. 503A category list PDF (May 14, 2026): why the injectable route dropped out
- 503A category list PDF (May 14, 2026): upcoming PCAC consultation on GHK-Cu. 503A category list PDF (May 14, 2026): upcoming PCAC consultation on GHK-Cu
What is not on an FDA page: The PCAC consultation on GHK-Cu that FDA says it intends to hold before the end of February 2027 has no FDA meeting page yet. Today the injectable route sits on the safety-risk page as nominated but withdrawn, while non-injectable GHK-Cu is in 503A Category 1 on the May 14, 2026 list; the field guide carries both as separate rows.
- 503A category list PDF 'Updated May 14, 2026': NON-injectable GHK-Cu is in Category 1; injectable is not. 503A category list PDF 'Updated May 14, 2026': NON-injectable GHK-Cu is in Category 1; injectable is not
- 503A category list PDF (May 14, 2026): why the injectable route dropped out. 503A category list PDF (May 14, 2026): why the injectable route dropped out
- 503A category list PDF (May 14, 2026): upcoming PCAC consultation on GHK-Cu. 503A category list PDF (May 14, 2026): upcoming PCAC consultation on GHK-Cu
What is not on an FDA page: The PCAC consultation on GHK-Cu that FDA says it intends to hold before the end of February 2027 has no FDA meeting page yet. Today non-injectable GHK-Cu is in 503A Category 1 on the May 14, 2026 list, and the Category 1 interim enforcement policy applies to it only under the conditions in FDA's January 2025 guidance.
- FDA safety-risks page (current as of 04/22/2026): Category 2 table row. FDA safety-risks page (current as of 04/22/2026): Category 2 table row
- FDA safety-risks page: ipamorelin acetate stated risk. FDA safety-risks page: ipamorelin acetate stated risk
- FDA safety-risks page: also in the 503A 'nominated but withdrawn' table. FDA safety-risks page: also in the 503A 'nominated but withdrawn' table
- 503B category list PDF 'Updated March 21, 2025': 503B Category 2 list includes Ipamorelin Acetate. 503B category list PDF 'Updated March 21, 2025': 503B Category 2 list includes Ipamorelin Acetate
- FDA 503A bulks page (current as of 05/14/2026): Category 2 definition. FDA 503A bulks page (current as of 05/14/2026): Category 2 definition
- FDA safety-risks page (current as of 04/22/2026): CJC-1295 stated risk. FDA safety-risks page (current as of 04/22/2026): CJC-1295 stated risk
- FDA safety-risks page: CJC-1295 immunogenicity. FDA safety-risks page: CJC-1295 immunogenicity